[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"icad---intracranial-atherosclerotic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:icad---intracranial-atherosclerotic-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100576811","stenting-for-ischemic-strokes-secondary-to-medically-refractory-intracranial-atherosclerotic-disease-100576811",false,"NCT06790147","Stenting for Ischemic Strokes Secondary to Medically Refractory Intracranial Atherosclerotic Disease","Stenting for Ischemic Strokes Secondary to Medically Refractory Intracranial Atherosclerotic Disease: STRICT-ICAS","STRICT-ICAS","Inclusion Criteria:\n\n* Adult patients with ICAD resulting in 70-99% vessel stenosis who undergo PTAS with any device\n* Patients will have to experience a stroke despite medical management involving risk factor modification and an antiplatelet agent\n* Baseline modified Rankin Scale (mRS) ≤ 3\n* Performance of the endovascular procedure at least 3 days after the last stroke\n\nExclusion Criteria:\n\n* Large vessel occlusion strokes undergoing rescue intracranial stenting will not be included\n* Baseline modified Rankin Scale (mRS) \\>3\n* Performance of the endovascular procedure less than 3 days after the last stroke.\n* Patients undergoing intracranial stenting for first stroke caused by ICAD\n* Adult patients with ICAD resulting in \\\u003C70% vessel stenosis","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to establish a prospective multicenter registry of patients undergoing intracranial stenting for ischemic strokes caused by medically refractory ICAD. The study aims to evaluate current practice patterns, periprocedural outcomes, and delayed outcomes.\n\nResearchers will collect demographic and procedural data from patients who undergo intracranial stenting after having an ischemic stroke caused by medically refractory ICAD.",[26,27],"ICAD - Intracranial Atherosclerotic Disease","Ischemic Stroke",[29,30,31],"ICAD","ischemic stroke","prospective registry","NOT_YET_RECRUITING","2025-05-14",{"date":35,"type":36},"2025-05-16","ACTUAL",{"date":38,"type":21},"2025-08",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Nitin Goyal","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100435326","drug-eluting-stenting-and-aggressive-medical-treatment-for-preventing-recurrent-stroke-in-intracranial-atherosclerotic-disease-trial-100435326","NCT04948749","Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial","Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)","DREAM-PRIDE","Inclusion Criteria:\n\n1. Age from 18 to 85 years\n2. Patients with ischemic stroke within 30 days of enrolment attributed to 70% to 99% stenosis of a major intracranial artery (internal carotid artery \\[C4-C7\\], middle cerebral artery \\[M1\\], vertebral artery \\[V4\\], or basilar artery) on CTA (According to WASID method)\n3. The diameter of the target vessel between 2.0mm - 4.5mm\n4. The stenosis lesion length ≤ 14 mm\n5. Baseline modified Rankin Scale (mRS) score ≤ 3\n6. Patient understands the purpose and requirements of the study, and has provided informed consent\n\nExclusion Criteria:\n\n1. Ischemic stroke occurred within 7 days before enrolment\n2. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion (NOTE: an exception is allowed if stenosis or occlusion involves a single vertebral artery proximal to a symptomatic basilar artery stenosis and the contralateral vertebral artery is supplying the basilar artery)\n3. Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which artery is symptomatic (NOTE: an exception is that if bilateral vertebral arteries with 70%-99% stenosis but unequal in size, the dominant side is considered as symptomatic)\n4. Unilateral vertebral artery stenosis of 70%-99% with normal contralateral vertebral artery\n5. Stroke caused by perforating artery occlusion\n6. CT angiographic evidence of severe calcification at target lesion\n7. Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 6 weeks\n8. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc\n9. History of stenting of an intracranial artery\n10. Presence of any unequivocal cardiac source of embolism\n11. Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation\n12. Cannot tolerate dual antiplatelet therapy\n13. Contraindications to heparin, rapamycin, contrast and local or general anesthesia\n14. Hemoglobin\\\u003C100g\u002FL, platelet count \\\u003C100×109\u002FL\n15. Severe hepatic and renal dysfunction\n16. INR\\>1.5 or there are uncorrectable factors leading to bleeding\n17. Major surgery within the past 30 days or planned within 90 days\n18. Renal artery, iliac artery, and coronary artery requiring simultaneous intervention\n19. Life expectancy \\\u003C1 year\n20. Pregnant or lactating women\n21. Cannot complete the follow-up due to cognitive, emotional or mental illness\n22. Other situations that are not suitable for enrolment according to the judgement of the investigator\n23. Enrolment in another study that would conflict with the current study","85 Years",{"count":55,"type":21},792,"INTERVENTIONAL",[58],"NA","The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.",[26,61,62,63,64,65],"ICAS - Intracranial Atherosclerosis","Drug-eluting Stent","Stroke","Drug Eluting Stents (DES)","Medical Treatment",[63,67,68,69,70,64],"Drug-eluting stent","Medical treatment","ICAD-Intracranial Atherosclerotic Disease","ICAS-Intracranial Atherosclerosis","RECRUITING","2024-12-25",{"date":74,"type":36},"2024-12-27",{"date":76,"type":36},"2021-07-02",{"date":78,"type":21},"2026-12",{"name":80,"class":43},"Beijing Tiantan Hospital",18,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":56,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":44},"100477919","phase-2-colchicine-use-in-intracranial-atherosclerotic-disease-100477919","NCT05503225","Colchicine Use in Intracranial Atherosclerotic Disease","Colchicine Use in Intracranial Atherosclerotic Disease - a Pilot Open-labelled Randomized Trial","Inclusion Criteria\n\n1. Chinese patients aged 40-80 years old\n2. Patients with symptomatic ICAD of ≥ 50% stenosis in middle cerebral arteries, basilar artery. Degree of stenosis will be quantified by computer tomographic angiography (CTA), magnetic resonance imaging (MRI) or digital subtraction angiography (DSA) by the WASID method (13). Symptomatic ICAD is defined as ischemic stroke or transient ischemic attack with clinical or radiological signs correspond to the vascular territory supplied by the disease vessel.\n3. Patients with first-ever ischaemic stroke within 8 weeks of recruitment\n\nExclusion Criteria\n\n1. Patients who are unable to provide an informed consent\n2. Patients who are contraindicated to contrast MRI scans, e.g. non-MRI compatible pacemaker, claustrophobia, known gadolinium-based contrast allergy, estimated glomerular filtration rate \\\u003C 30mL\u002Fmin\u002F1.73m2, etc.\n3. Patients who have absolute or relative contraindications to colchicine therapy, e.g. colchicine allergy, neuromuscular disorders, haematological diseases, chronic diarrhea, estimated glomerular filtration rate \\\u003C 30mL\u002Fmin\u002F1.73m2, chronic liver disease, etc.\n4. Patients with intracranial stenosis not due to atherosclerosis, e.g. vasculitis, vasospasm, Moyamoya disease, etc.\n5. Pregnancy\n6. Patients with elevated creatine kinase level at randomisation stage of study.\n7. Recurrent gouty arthritis that requires colchicine for \\> 3 months per year;\n8. Inflammatory bowel disease or chronic diarrhea;\n9. Neuromuscular disease or a nontransient creatine kinase level that was greater than three times the upper limit of the normal range (unless due to infarction) for \\> 3 months;\n10. Clinically significant nontransient hematologic abnormalities with hemoglobin \\\u003C10g\u002FdL, white blood cell \\\u003C 4x10\\^9, or platelet \\\u003C 100x10\\^9\u002FL for \\> 3 months;\n11. Alcoholism;\n12. Long term systemic glucocorticoid therapy","40 Years","80 Years",{"count":92,"type":21},72,[94],"PHASE2","Intracranial atherosclerotic disease (ICAD) is a major ischaemic stroke aetiology in Asia. Influenced by genetics, lifestyle and metabolic risk factors. From the SAMMPRIS cohort, 1-year stroke recurrence risk was 13% even with intensive medical therapy.\n\nIn this pilot randomized, double-blind, placebo-controlled trial, the investigators shall recruit 44 patients with recent ischaemic stroke due to intracranial atherosclerosis (ICAD) with ≥ 50% stenosis. Patients will be randomly assigned to either low-dose colchicine (0.5mg daily) (n=22) or placebo (n=22) for 12 months. High-resolution magnetic resonance vessel wall imaging will be performed at baseline and 12 months. The primary endpoint is a composite of regression of intracranial stenosis, plaque volume, or occurrence of any major adverse cardio- or cerebrovascular events at 12 months. The investigators shall also evaluate safety endpoints including diarrhea, marrow suppression, infections, neuromuscular dysfunction.\n\nNo studies had focused on the use of colchicine in patients with ICAD, which is highly prevalent in Asia. Results from this pilot trial will provide an important basis for a larger-scale main trial in the future.",[26],[29,98,99],"CVA","colchicine","2024-09-02",{"date":102,"type":36},"2024-09-04",{"date":104,"type":36},"2022-11-28",{"date":106,"type":21},"2026-05-31",{"name":108,"class":43},"Chinese University of Hong Kong"]